BACKGROUND: Both normal and malignant plasma cell (PC) populations can be identified using modern flow cytometry (FC) technique in multiple myeloma (MM) patients. Expression of CD19 and CD56 markers is heterogenous on bone marrow PCs of healthy individuals. Little is known about immunophenotypically aberrant (CD19-/CD56+) PCs subpopulation of healthy people. METHODS: Using six color FC, we analyzed PCs in BM samples of 11 healthy donors (HD) and compared their immunophenotypic properties with clonal PC populations from MM patients. RESULTS: Both immunophenotypically normal (CD19+/CD56-) and aberrant (CD19-/CD56+) PC populations could be detected in 10 of 11 HDs' BM samples and constituted the median of 60.3% (37.3-72.3) and 9.6% (0-35.7) of BM PCs, respectively. CD19, CD56, CD38, CD45, and CD20 marker expression characteristics were of little value discriminating clonal PCs of MM patients from immunophenotypically aberrant PCs of healthy donors. CONCLUSIONS: Our findings suggest that aberrant immunophenotype is common in BM PCs of healthy people. Improvements in FC methodology to separate normal and malignant PCs remain an open area for future investigations.
BACKGROUND: Both normal and malignant plasma cell (PC) populations can be identified using modern flow cytometry (FC) technique in multiple myeloma (MM) patients. Expression of CD19 and CD56 markers is heterogenous on bone marrow PCs of healthy individuals. Little is known about immunophenotypically aberrant (CD19-/CD56+) PCs subpopulation of healthy people. METHODS: Using six color FC, we analyzed PCs in BM samples of 11 healthy donors (HD) and compared their immunophenotypic properties with clonal PC populations from MMpatients. RESULTS: Both immunophenotypically normal (CD19+/CD56-) and aberrant (CD19-/CD56+) PC populations could be detected in 10 of 11 HDs' BM samples and constituted the median of 60.3% (37.3-72.3) and 9.6% (0-35.7) of BM PCs, respectively. CD19, CD56, CD38, CD45, and CD20 marker expression characteristics were of little value discriminating clonal PCs of MMpatients from immunophenotypically aberrant PCs of healthy donors. CONCLUSIONS: Our findings suggest that aberrant immunophenotype is common in BM PCs of healthy people. Improvements in FC methodology to separate normal and malignant PCs remain an open area for future investigations.
Authors: Steven R Post; Ginell R Post; Dejan Nikolic; Rebecca Owens; Giovanni Insuasti-Beltran Journal: Cytometry B Clin Cytom Date: 2018-04-06 Impact factor: 3.058
Authors: R Gupta; P Gupta; K Rahman; S Biswas; D Chandra; M K Singh; M K Sarkar; A Gupta; S Nityanand Journal: Indian J Hematol Blood Transfus Date: 2021-08-10 Impact factor: 0.915
Authors: Prashant R Tembhare; Constance M Yuan; David Venzon; Raul Braylan; Neha Korde; Elisabet Manasanch; Diamond Zuchlinsky; Katherine Calvo; Roger Kurlander; Manisha Bhutani; Nishant Tageja; Irina Maric; Marcia Mulquin; Mark Roschewski; Mary Kwok; David Liewehr; Ola Landgren; Maryalice Stetler-Stevenson Journal: Leuk Res Date: 2013-12-11 Impact factor: 3.156
Authors: Jun Hee Lim; James Q Wang; Fiona Webb; Kartik Saxena; Daniel Enosi Tuipulotu; Abhimanu Pandey; Si Ming Man; Dipti Talaulikar Journal: iScience Date: 2022-08-04